Autres langues Nippon Shinyaku Co., Ltd.

Actions

4516

JP3717600005

Temps Différé Japan Exchange Autres places de cotation 04:30:00 14/05/2024			Varia. 5j.	Varia. 1 janv.
3 888 ^JPY	-0,13%		-11,31%	-22,14%

10/04	NIPPON SHINYAKU CO., LTD. : Jefferies & Co. reste à l'achat	ZM
09/02	Vicore Pharma signe un accord de licence pour son candidat médicament contre la fibrose pulmonaire idiopathique	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Nippon Shinyaku : Outline of Consolidated Financial Results for the Year Ended March 31, 2024	10/05
Interim report January-March 2024	03/05
Nippon Shinyaku : Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW	16/04
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases	05/04
Nippon Shinyaku : Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System	04/04
Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan	26/03
Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan	26/03
Nippon Shinyaku : Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan	25/03
Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	18/03
VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data presented at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	06/03
Year-end report 2023	28/02
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	09/02
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan	09/02
Nippon Shinyaku : The European Commission Grants Orphan Drug Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy	21/12
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (2Q FY2023)(Script+Q&A(Summary))P	07/12
Capricor Therapeutics Announces $23 Million Registered Direct Offering	02/10/23
The Menarini Group Announces ELZONRIS Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare	31/08/23
Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2023	10/08/23
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (1Q FY2023	10/08/23
Nippon Shinyaku : Outline of Consolidated Financial Results for the First Quarter Ende	10/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Nippon Shinyaku Co., Ltd.

Actions

4516

JP3717600005

Autres langues

Filtres